200 related articles for article (PubMed ID: 36271205)
1. Microdialysis of Voriconazole and its N-Oxide Metabolite: Amalgamating Knowledge of Distribution and Metabolism Processes in Humans.
Schulz J; Michelet R; Zeitlinger M; Mikus G; Kloft C
Pharm Res; 2022 Dec; 39(12):3279-3291. PubMed ID: 36271205
[TBL] [Abstract][Full Text] [Related]
2. Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N-oxide.
Schulz J; Michelet R; Zeitlinger M; Mikus G; Kloft C
Pharm Res; 2022 Nov; 39(11):2991-3003. PubMed ID: 36171344
[TBL] [Abstract][Full Text] [Related]
3. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis.
Kirbs C; Kluwe F; Drescher F; Lackner E; Matzneller P; Weiss J; Zeitlinger M; Kloft C
Eur J Pharm Sci; 2019 Apr; 131():218-229. PubMed ID: 30731238
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
Hu L; Huang S; Huang Q; Huang J; Feng Z; He G
PLoS One; 2023; 18(9):e0288794. PubMed ID: 37695751
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
Hu L; Huang Q; Huang S; Feng Z
Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
[TBL] [Abstract][Full Text] [Related]
7. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
Wang X; Zhao J; Wen T; Liao X; Luo B
Pharmacology; 2021; 106(3-4):202-210. PubMed ID: 32998136
[TBL] [Abstract][Full Text] [Related]
8. A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices for biomedical applications.
Schulz J; Michelet R; Joseph JF; Zeitlinger M; Schumacher F; Mikus G; Kloft C
J Pharm Biomed Anal; 2022 Feb; 210():114551. PubMed ID: 34999435
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
[TBL] [Abstract][Full Text] [Related]
12. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
13. Saturated Metabolism of Voriconazole N-Oxidation Resulting in Nonlinearity of Pharmacokinetics of Voriconazole at Clinical Doses.
Yamada T; Mino Y; Yagi T; Naito T; Kawakami J
Biol Pharm Bull; 2015; 38(10):1496-503. PubMed ID: 26424015
[TBL] [Abstract][Full Text] [Related]
14. Optimization of Voriconazole Dosing Regimens Against Aspergillus Species and Candida Species in Pediatric Patients After Hematopoietic Cell Transplantation: A Theoretical Study Based on Pharmacokinetic/Pharmacodynamic Analysis.
Xie M; Jiang M; Qiu H; Rong L; Kong L
J Clin Pharmacol; 2023 Sep; 63(9):993-1001. PubMed ID: 37083934
[TBL] [Abstract][Full Text] [Related]
15. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.
Gautier-Veyret E; Fonrose X; Tonini J; Thiebaut-Bertrand A; Bartoli M; Quesada JL; Bulabois CE; Cahn JY; Stanke-Labesque F
Antimicrob Agents Chemother; 2015 Apr; 59(4):2305-14. PubMed ID: 25645831
[TBL] [Abstract][Full Text] [Related]
16. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit.
Lin XB; Huang F; Tong L; Xia YZ; Wu JJ; Li J; Hu XG; Liang T; Liu XM; Zhong GP; Cai CJ; Chen X
Int J Infect Dis; 2020 Apr; 93():345-352. PubMed ID: 32109625
[TBL] [Abstract][Full Text] [Related]
20. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
Yamada T; Mino Y; Naito T; Kawakami J
J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
